News

Platinum-Doublet Chemo Shows Efficacy as a Second-Line Treatment for Relapsed SCLC

05/06/2021

For patients with relapsed SCLC, second-line, platinum-doublet chemotherapy may be beneficial over non-platinum regimens.

For patients with relapsed SCLC,...

05/06/2021

Oncology

News

PD-L1 Inhibitor Plus Etoposide-Platinum Regimen Promising for Extensive-Stage SCLC

11/11/2020

Results from a systematic review show that a PD-L1 inhibitor plus etoposide-based chemotherapy could be an optimal first-line treatment for ES-SCLC.

Results from a systematic review...

11/11/2020

Oncology

News

Basics of Immunotherapy in SCLC

10/03/2020

In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Stephen V. Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C, shared insight on immunotherapy treatment for SCLC.

In a session presented at the...

10/03/2020

Oncology

News

No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC

08/24/2020

In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.

In patients with SCLC,...

08/24/2020

Oncology

News

First-Line Pembrolizumab Combo Improves PFS in Patients With Extensive-Stage SCLC

06/22/2020

First-line therapy with pembrolizumab plus etoposide and platinum (EP) led to significantly improved PFS compared with placebo plus EP in patients with ES-SCLC.

First-line therapy with...

06/22/2020

Oncology

News

FDA Approves Lurbinectedin for Adults With Metastatic SCLC

06/15/2020

The FDA has approved lurbinectedin for the treatment of adults with metastatic SCLC that progressed during or after platinum-based chemotherapy.

The FDA has approved...

06/15/2020

Oncology

News

Second-Line Lurbinectedin Shows Activity, Acceptable Safety in SCLC

05/12/2020

In a phase 2 study of patients with SCLC, second-line lurbinectedin was active and yielded a manageable safety profile.

In a phase 2 study of patients...

05/12/2020

Oncology

News

FDA Approves Durvalumab–Chemo Combo for Extensive-Stage SCLC

03/30/2020

The FDA has approved durvalumab plus etoposide and carboplatin or cisplatin for the first-line treatment of patients with extensive-stage SCLC.

The FDA has approved durvalumab...

03/30/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology